|Axovan Ltd., Allschwil (CH)
Active in pharmaceutical research and development, Axovan is focusing its efforts on a broad family of potential drug targets called G Protein-Coupled Receptors (GPCRs). The company has biology and screening capacity as well as medicinal and combinatorial chemistry capabilities and increasingly also drug development capabilities. In addition Axovan has developed a validated GPCR-biased chemical library through its AXADDIS chem-informatics predictive platform. Axovan intends to license out, at various stages of development, compounds resulting from its research to pharmaceutical or biotech partners. Since 2002 the company has a compound inlicensed from Roche in clinical development. Axovan owns worldwide rights for this injectable endothelin antagonist (Clazosentan) to be developed for the prevention and treatment of vasospasm following subarachnoid hemorrhage (SAH) and conducted a phase II study in Germany which showed that Clazosentan is safe and well tolerated in patients. In addition, the results are indicative of a substantial effect of the drug in reducing the incidence and severity of post-SAH vasospasm.
In October 2003 Actelion Ltd. (SWX:ATLN) acquired 100 % of the outstanding shares of Axovan. Depending on milestones the purchase price can amount up to CHF 252m.